Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2910319 | 0.85 | ALDH1A1 (0.40) | USP2LMNATSHRHSD17B10DGAT1 | |
| SCHEMBL28185554 | 0.82 | LMNA (0.42) | USP2LMNATSHRHSD17B10RECQL | |
| SCHEMBL242271 | 0.82 | GAA (0.39) | USP2LMNATSHRHSD17B10DGAT1 | |
| SCHEMBL2420651 | 0.82 | USP2 (0.37) | USP2LMNATSHRHSD17B10DGAT1 | |
| SCHEMBL8094600 | 0.80 | LMNA (0.44) | USP2LMNATSHRHSD17B10RECQL | |
| SCHEMBL2420820 | 0.79 | ALDH1A1 (0.41) | USP2LMNATSHRHSD17B10DGAT1 | |
| SCHEMBL8102543 | 0.79 | LMNA (0.47) | USP2LMNATSHRHSD17B10RECQL | |
| SCHEMBL8094624 | 0.79 | LMNA (0.47) | USP2LMNATSHRHSD17B10RECQL | |
| SCHEMBL28853168 | 0.79 | LMNA (0.47) | USP2LMNATSHRHSD17B10RECQL | |
| SCHEMBL2830033 | 0.79 | TSHR (0.42) | USP2LMNATSHRHSD17B10DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4385529-A2 | DEVICES FOR CONTROLLED DELIVERY | Femasys, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-3787533-B1 | DEVICES FOR CONTROLLED DELIVERY | FEMASYS INC (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20230390105-A1 | METHODS AND DEVICES FOR CONTROLLED DELIVERY | POINTILLIST GLOBAL MACRO SERIES OF POINTILLIST PARTNERS LLC | 2023-12-07 | — | — | US | disclosed |
| US-20230329900-A1 | METHODS AND DEVICES FOR CONTROLLED DELIVERY | FEMASYS INC. | 2023-10-19 | — | — | US | disclosed |
| US-11744729-B2 | Methods and devices for controlled delivery | FEMASYS INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20190336325-A1 | METHODS AND DEVICES FOR CONTROLLED DELIVERY | FEMASYS INC. | 2019-11-07 | — | — | US | disclosed |
| US-20130089505-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | VALOR MEDICAL, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2219553-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | Valor Medical, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090257976-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | VALOR MEDICAL, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009064698-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | VALOR MEDICAL, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089505-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | MMAB, CBL, ECPAS | USP2 373/4885LMNA 727/4885TSHR 4870/4885 |
| US-20090257976-A1 | SINGLE VIAL FORMULATION FOR MEDICAL GRADE CYANOACRYLATE | MMAB, CBL, ECPAS | USP2 373/4885LMNA 727/4885TSHR 4870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.